Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biologi… (NCT05169593) | Clinical Trial Compass
RecruitingPhase 4
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
Belgium292 participantsStarted 2022-09-08
Plain-language summary
With this prospective, randomized, multicentre, parallel group pragmatic non-inferiority trial, the investigators will evaluate if endoscopy-driven introduction of biological therapy is not leading to more postoperative endoscopic recurrence at week 86 compared to systematic prophylactic biological therapy in patients with CD undergoing an ileocolonic resection with ileocolonic anastomosis. Secondary analyses will include influence on clinical, biological and surgical CD recurrence, serious adverse events, direct costs, work productivity, and quality of life. If the investigators can demonstrate the non-inferiority of an endoscopy-driven approach, this patient-tailored management could be advocated, while a more expensive systematic introduction of biological therapies could be limited.
Finally, endoscopic images provided through the SOPRANO CD study, will be used to develop a new scoring system evaluating postoperative endoscopic recurrence.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
✓. Patients with a diagnosis of Crohn's disease based on radiology, endoscopy and/or histology
✓. Males and females 18-80 years old.
✓. Patients undergoing an ileocolonic resection with ileocolonic anastomosis (with or without temporary ileostomy) within 3 and 40 days prior to the Screening visit.
✓. Patients having an increased risk for postoperative recurrence for any of the following reasons:
✓. Penetrating disease as reason for ileocolonic resection
✓. Previous ileocolonic resection within ten years of index surgery
✓. Two or more previous ileocolonic resections
Exclusion criteria
✕. Participant has a history of primary non response or secondary loss of response to all five biological therapies of interest, namely adalimumab, infliximab, ustekinumab, vedolizumab and risankizumab..